Addition of incretin therapy to metformin in type 2 diabetes

• Published in: The Lancet (British edition) Vol. 375; no. 9724; pp. 1410 - 1412
• Main Authors: Scheen, André J, Radermecker, Régis P
• Format: Journal Article Web Resource
• Language: English
• Published: England Elsevier Ltd 24-04-2010; Elsevier Limited; Lancet Publishing Group
• Subjects: Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Drug Therapy, Combination; Endocrinologie, métabolisme & nutrition; Endocrinology, metabolism & nutrition; Glucagon-Like Peptide 1; Human health sciences; Humans; Hypoglycemic Agents - therapeutic use; incretin; Incretins - therapeutic use; Internal Medicine; metformin; Metformin - therapeutic use; Pharmacie, pharmacologie & toxicologie; Pharmacy, pharmacology & toxicology; Sciences de la santé humaine; type 2 diabetes
• ISSN: 0140-6736; 1474-547X; 1474-547X
• DOI: 10.1016/S0140-6736(10)60399-6

Findings from today's study show the superiority of 1.8 mg versus 1.2 mg liraglutide for reduction of HbA^sub 1c^, but this result has not been recorded in previous studies (table).7 Only the 1.8 mg dose of liraglutide was assessed in LEAD-6,2 in which liraglutide once daily was shown to be superior to 10 µg exenatide twice daily for reduction of HbA^sub 1c^. [...] 1.2 mg liraglutide should be considered as the starting dose in most patients with type 2 diabetes, with recommendations for titration up to 1.8 mg if target HbA^sub 1c^ concentrations are not reached.